Skip to content

Treatment of psychiatric and neurocognitive sequelae of COVID-19 disease in adolescents and young adults

Treatment of psychiatric and neurocognitive sequelae of COVID-19 disease in adolescents and young adults

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00032428
Enrollment
16
Registered
2024-04-18
Start date
2024-01-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F06.8 U09.9

Interventions

Group 1: Psychoeducational and mindfulness-based psychotherapy group (8 appointments of 90min each). Pre- and post-participation psychiatric and cognitive diagnostics.

Sponsors

Klinikum Karlsbad Langensteinbach
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 21 Years

Inclusion criteria

Inclusion criteria: Diagnosis of psychiatric or cognitive disorders following an COVID-19 infection (Post COVID syndrome)

Exclusion criteria

Exclusion criteria: - no evidence of past infection with SARS-CoV-2 - age under 15 or above 21 years

Design outcomes

Primary

MeasureTime frame
Determination before and after therapy of: BDI-FS - Beck Depression Inventory Fast Screen BSCL - Brief Symptom Check List FSMC - Fatigue Skala for Motoric and Cognition PEM -DSQ - Postexertional Malaise DePaul Symptom Questionnaire MADRS - Montgomery Asberg Depression Rating Scale COGBAT - Cognitive Basic Assesment MKS - Marburg Competence Scale ILK - Inventory on Quality of Life in Children and Adolescents

Countries

Germany

Contacts

Public ContactMatthias Weisbrod

Klinikum Karlsbad Langensteinbach

matthias.weisbrod@srh.de+497202 61-6363

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026